Award
National Cancer Institute 3R01CA263806-05S2
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
Recipient
UNIVERSITY OF CALIFORNIA-IRVINE
Award Amount
$80,303.00
Ceiling
$80,303.00
Awarded
August 27, 2025
Identifier
3R01CA263806-05S2
The award supports research to inhibit p38MAPK/JNK pathways to prevent neuronal damage caused by cisplatin chemotherapy, aiming to reduce cognitive and neuropathic side effects in cancer treatment.
Description
This project aims to determine if inhibition of the p38MAPK/JNK pathways can prevent cisplatin-induced neuronal apoptosis and damage, leading to attenuation of cognitive impairments, gait changes, and neuropathic pain associated with chemotherapy-related cognitive impairment (CRCI) and chemotherapy-induced peripheral neuropathy (CIPN). The approach includes in vitro analysis of neuronal cell lines, behavioral analysis using sensory testing for CIPN, cognitive testing, and gait analysis in female mice using two cancer models. The studies will demonstrate the role of p38MAPK and JNK in cisplatin-induced CRCI/CIPN and explore translational strategies to treat these side effects, focusing on improving quality of life for women with cancer.